Severity and Its Contributing Factors in Patients With Vestibular Migraine: A Cohort Study

Wei Liu, Hongli Dong, Le Yang, Hongru Zhao, Wanli Dong and Yi Yang

Objective: As a recently defined disease entity, vestibular migraine (VM) is a variant of migraine with broad spectrum of manifestations. We evaluated a prospective cohort of patients with VM in two centers to assess severity of VM attacks and investigate its contributing factors in patients with VM.

Methods: Adult participants with the diagnosis of VM or probable VM were enrolled according to the 2012 International Headache Society-Bárány Society Criteria. Every outpatient was followed up for 6 months to record the occurrence of VM attacks. Clinical data such as age, sex, number of VM attacks, severity on the visual analog scale, and lipid intake were collected and analyzed. Generalized Anxiety Disorder-7, Patient Health Questionnaire-9, Horne and Ostberg Morningness-Eveningness Questionnaires, and Pittsburgh Sleep Quality Index were also administered to find contributing factors.

Results: During a 6-month clinical follow-up, 313 VM attack were reported. According to the Visual Analog Scale, the patients were divided into two groups. Then univariate and multivariable analyses were conducted. Among the risk factors, duration of illness (adjusted OR, 1.041; 95% CI, 1.010–1.073; \( P = 0.009 \)), time of onset: 00:00:00–12:00:00 (adjusted OR, 3.961; 95% CI, 1.966–7.979; \( P < 0.001 \)) and PSQI scores (adjusted OR, 1.086; 95% CI, 1.002–1.178; \( P = 0.046 \)) were significantly associated with the severity of VM attack assessed by VAS.

Conclusion: The data suggest that patients tended to experienced more severe VM attacks in early hours of a day, especially for those sufferers with longer duration of illness or poor sleep quality. Targeted management of such factors is required to reduce the severity of attacks.

Keywords: vestibular migraine, severity, clinical presentation, contributing factors, circadian variations

INTRODUCTION

Vestibular migraine (VM), as the most common cause of episodic vertigo, is a disease with significant impact on the quality of life for those afflicted (1, 2). The diagnosis and treatment of VM are challenged by its broad manifestation spectrum, uncertain triggers, and complex comorbidities (3).
For VM patients, they may have very different onset time or clinical manifestations in different attacks (3, 4). The evaluation of these patients’ subjective dysfunction and psychological status, which causes some considerable difficulties in daily life, is useful to further understand the disease process (5). Meanwhile, various triggers are frequently reported by VM patients, but its contributing factors and pathophysiology are still uncertain (4, 6). To explore the self-awareness and related clinical manifestations of VM patients is helpful to formulate more specific intervention measures.

In this study, we explored the demographic and clinical characteristics of VM patients with a 6-month follow-up. At the same time, we assessed the severity of VM attacks and investigated its related risk factors.

**METHODS**

**Study Population**

Participants were recruited to meet the 2012 International Headache Society-Bárán Society Criteria, which were included in the third version of the International Classification of Headache Disorder for VM or possible VM (7, 8) from September 2014 to May 2018 at the neurology outpatient clinics of the First Affiliated Hospital of Soochow University and Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine (as seen in **Table 1**). The diagnoses were made by two senior neurologists and one senior otolaryngologist.

The initial sample included 675 persons. The exclusion criteria were as follows: (1) < 18 years old; (2) during the follow-up period, no attack or loss of follow-up was reported; (3) inability to complete questionnaires within 72 h after attack; (4) headache or vestibular symptoms attributed to secondary causes; (5) long-term users (more than 2 weeks) of migraine-suppressing drugs such as low-dose tricyclic antidepressants, calcium channel blockers, or beta-blockers; (6) long-term users (more than 2 weeks) of hypnotics; (7) users of oral contraceptives; (8) history of drug abuse; (9) history of head trauma, otolaryngology surgery, or intracranial infection; (10) shift work.

Only 351 patients with VM or probable VM were included in the present study. A 6-month clinical follow-up was performed. Nine patients were lost for 342/351 (97.4%) of the patients, and 35 patients did not report any attack during the follow-up. Finally, 307 participants (241 definite VM and 66 probable VM) formed the basis of this report. All patients received the same advice, including sleep hygiene, physical exercise, identifying and blocking the triggers of migraine.

**Outcome Variable**

The main outcome measures were VM episodes reported by patients during follow-up (from June 01, 2019 until the end of the follow-up on December 31, 2019). The recruited patients were followed up for inter-ictal phase by telephone and emails. If a participant reported any form of seizure, she/he was interviewed by two neurologists and record their characteristics. All self-reported attack cases and diagnostic dates were verified using participants’ hospital records and information collected from their physicians. Participants were allowed to take acute medications according to their medical conditions. We recorded and classified the sensation descriptions of patients during VM episodes according to the definitions of the Committee for Classification of Vestibular Disorders of the Bárány Society in 2012 and “Classification of Vestibular Symptoms” of the Bárány Society in 2009 (8, 9).

**Evaluation of Severity**

Visual analog scale (VAS) was used to assess patients’ subjective perception of severity, including but not limited to vestibular symptoms, headache symptoms, visual symptoms, and ictal aural symptoms (VAS was classified as follows: 0–3, mild; 4–6, moderate; and 7–10, severe) (10, 11). All participants were asked to complete the VAS scale with the assistance of a neurologist within 6 h of the self-report. Each participant was asked to answer three times, with an hour interval between each inquiry. The final VAS score was the average value of these three times.

**Baseline Information and Measurement of the Covariates**

Each participant took part in a face-to-face interview by trained staff to collect baseline data. Demographic information, lifestyles (drinking or caffeine intake), family history, and health history (e.g., self-reported or physician diagnosed motion sickness) were gathered. Family history was defined as the reporting of similar vestibular symptoms by blood related family members (lasting more than 5 min to a few days) with no clear diagnosis or with migraine. Lctal aural symptoms were defined as tinnitus, ear fullness/pressure, and/or muffled hearing (these symptoms were binaural or monaural) (12). Visual symptoms were defined as visual aura, visual blurring, eye strain, and/or visual distortions (these symptoms were binocular or monocular) (12).

Those participants who fulfilled the inclusion criteria completed the following questionnaires in 72 h after attack: (1) a Chinese translation of Horne and Ostberg Morningness-Eveningness Questionnaires (MEQ) was used to assess the participants’ chronotype (13); (2) the Generalized Anxiety Disorder-7 (GAD-7) was used to estimate the patient’s anxiety level (14); (3) the Patient Health Questionnaire-9 (PHQ-9) was used to estimate the patient’s level of depression (15); (4) the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) was used to assess sleep quality (16); the Chinese version of PSQI also showed high reliability (Cronbach’s coefficient = 0.83), and the best cut-off point was 5 (16); (5) a validated semiquantitative food frequency questionnaire was used to examined recent food intake patterns (on average over the previous 2 week; high-lipid diet: the total lipid intake was > 100 g daily; alcohol or caffeine consumption: take in weekly or more often) (17, 18).

**Data Analyses**

Continuous variables were analyzed as mean and standard deviation or the median and interquartile range while categorical variables were analyzed as frequency and percentage, properly. Student’s t-test, Mann-Whitney U test or Chi-square test was used to assessed differences among variables. Pearson’s correlation coefficients were calculated to assess the relationship between the variables. Logistic regression analysis was used to...
find risk factors associated with severity of attack in patients with VM after adjusting for other variables selected from univariate analyses. Therefore, no priori power analysis was conducted to calculate sample size. The level of significance for these descriptive comparisons was established at 0.05 for two-sided hypothesis testing. Statistical analysis was performed in SPSS 25.0 and R programming language (3.6.3).

RESULTS

Participants and Their Demographics and Characteristics

A total of 307 patients with VM were included in our study; only four (1.3%) of them reported two attacks, two (0.6%) of them reported three attacks. As the number of participants with multiple attacks was very small, no useful separate analysis could be made. Therefore, we identified their first attacks during the follow-up period to further analysis. Patient selection is illustrated in Figure 1.

Among our subjects, just 28.00% were males (221 women, 86 men); the age was 42.0 (35.0, 52.0) years old; the duration of illness was 4.0 (1.0, 9.0) years; 155 patients (50.50%) reported a family history of similar episodic vestibular symptoms. Most sufferers (73.60%) experienced VM attacks in early hours (00:00:00–12:00:00); ictal aural symptoms, visual symptoms, alcohol consumption, high-fat diet, family history, time of onset (00:00:00–12:00:00); ictal aural symptoms, visual symptoms, alcohol consumption, high-fat diet, family history, time of onset (00:00:00–12:00:00); time of onset, gender, age, age of first onset, duration of illness, alcohol and caffeine consumption, high-fat diet, history of motion sickness, family history, ictal aural symptoms, visual symptoms, length of spell, VAS, GAD-7, PHQ-9, PSQI, and MEQ scores and observed correlation coefficients: $r = -0.342$ between the time of VM attacks and VAS ($p < 0.001$); $r = 0.233$ between the PSQI scores and VAS ($p < 0.001$); $r = 0.175$ between the GAD-7 scores and VAS ($p < 0.001$); VAS had weak but significant correlations with attack time, recent sleep quality, and anxiety (Table 4).

Contributing Factors Associated With Severity of Attacks in VM

Univariate and multivariable logistic regression analyses were used to identify the risk factors associated with severe attack in VM patients. Model were established for group of confounding factors: gender, duration of illness, history of motion sickness, family history, time of onset (00:00:00–12:00:00); ictal aural symptoms, visual symptoms, alcohol consumption, high-fat diet,
M1 participants were recruited to meet the 2012 International Headache Society-Bárány Society Criteria for VM or possible VM from September 2014 to May 2018 in 2 centers N = 675

excluded according to the criteria -324

M2 a 6-month clinical follow-up was performed on remained participants N = 351

excluded persons without follow-up information -9

M3 N = 342

excluded patients did not report any attack during the follow-up -35

M4 N = 307

definite VM N = 241
probable VM N = 66

FIGURE 1 | Flow diagram of participants' selection.
### TABLE 2 | The characteristics of patients with VM.

| Characteristics                  | Patients (N = 307) |
|----------------------------------|-------------------|
| Age, years, median (IQR)         | 42.00 (35.00, 52.00) |
| Male, n (%)                      | 86 (28.00)        |
| Age of first onset, median (IQR) | 36.00 (30.00, 44.00) |
| Duration of illness, years, median (IQR) | 4.00 (1.00, 9.00) |
| History of motion sickness, n (%) | 126 (41.00)       |
| Family history, n (%)            | 155 (50.50)       |
| High-fat diet, n (%)             | 12 (3.90)         |
| Alcohol consumption, n (%)       | 29 (9.40)         |
| Caffeine consumption, n (%)      | 11 (3.60)         |
| Time of onset, n (%)             |                   |
| 00:00:00–12:00:00                | 226 (73.60)       |
| 12:00:00–24:00:00                | 81 (26.40)        |
| Length of spell, hours, median (IQR) | 2.00 (0.50, 8.00) |
| Ictal aural symptoms, n (%)      | 47 (15.30)        |
| Visual symptoms, n (%)           | 48 (15.60)        |
| VAS, median (IQR)                | 6.00 (5.00, 8.00) |
| GAD-7, median (IQR)              | 11.00 (8.00, 14.00) |
| PHQ-9, median (IQR)              | 9.00 (7.00, 12.00) |
| PSQI, median (IQR)               | 8.00 (6.00, 10.00) |
| MEQ, median (IQR)                | 56.00 (50.00, 63.00) |

VAS, Visual Analogs Scale; GAD-7, Generalized Anxiety Disorder-7; PHQ-9, Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index. MEQ, Horne and Ostberg Morningness-Eveningness Questionnaires.

PSQI, and GAD-7. From the univariate logistic analysis, duration of illness (OR, 1.033; 95% CI, 1.005–1.062; \( P = 0.019 \)), time of onset (00:00:00–12:00:00, OR, 4.682; 95% CI, 2.553–8.584; \( P < 0.001 \)), PSQI (OR, 1.119; 95% CI, 1.039–1.205; \( P = 0.003 \)) and GAD-7 (OR, 1.096; 95% CI, 1.030–1.166; \( P = 0.004 \)) were found to be significantly associated with severity of VM attack (Table 5). After adjusting for other variables selected from univariate analyses, multivariable logistic regression analysis was used to determine factors that were associated with the severity of VM attack. Our results indicated that only duration of illness (adjusted OR, 1.041; 95% CI, 1.010–1.073; \( P = 0.009 \)), time of onset (00:00:00–12:00:00, adjusted OR, 3.961; 95% CI, 1.966–7.979; \( P < 0.001 \)) and PSQI scores (adjusted OR, 1.086; 95% CI, 1.002–1.178; \( P = 0.046 \)) were significantly associated with the severity of VM attack assessed by VAS. However, gender, history of motion sickness, family history, ictal aural symptoms, visual symptoms, alcohol consumption, high-fat diet and GAD-7 scores showed no association with the severity of VM attack (\( P > 0.05 \), Table 5).

**DISCUSSION**

In our study, the severity of the attack in VM patients was analyzed with clinical data as well as related psychological parameters. The main results are as follows: (1) patients...
TABLE 3 | Comparison of demographic, clinical and psychometric characteristics between groups of VM patients with high and low VAS.

| Characteristics                        | VAS ≥ 7 (N = 137) | VAS < 7 (N = 170) | P   |
|----------------------------------------|-------------------|-------------------|-----|
| Age, years, median (IQR)               | 44.00 (36.00, 56.50) | 41.00 (36.00, 49.00) | 0.041 |
| Male, n (%)                            | 40 (29.2)         | 46 (27.1)         | 0.678 |
| Age of first onset, median (IQR)       | 36.00 (29.50, 45.00) | 36.50 (30.75, 42.00) | 0.665 |
| Duration of illness, years, median (IQR) | 5.00 (2.00, 11.00) | 3.00 (1.00, 7.00) | 0.023 |
| History of motion sickness, n (%)      | 59 (43.1)         | 67 (39.4)         | 0.518 |
| Family history, n (%)                  | 70 (51.1)         | 85 (50.0)         | 0.849 |
| Time of onset, n (%)                   | 121 (88.3)        | 105 (61.8)        | <0.001 |
| Length of spell, hours, median (IQR)   | 3.00 (0.50, 3.00) | 2.00 (0.33, 15.50) | 0.303 |
| Ictal aural symptoms, n (%)            | 22 (16.1)         | 25 (14.7)         | 0.744 |
| Visual symptoms, n (%)                 | 17 (12.4)         | 31 (18.2)         | 0.162 |
| Alcohol consumption, n (%)             | 14 (10.2)         | 15 (8.8)          | 0.678 |
| Caffeine consumption, n (%)            | 6 (4.4)           | 5 (2.9)           | 0.548 |
| High-fat diet, n (%)                   | 6 (4.4)           | 6 (3.5)           | 0.702 |
| GAD-7, median (IQR)                    | 12.00 (9.00, 15.00) | 10.00 (8.00, 13.00) | 0.005 |
| PHQ-9, median (IQR)                    | 9.00 (7.00, 12.00) | 9.00 (6.00, 11.00) | 0.239 |
| PSQI, median (IQR)                     | 8.00 (6.00, 11.00) | 8.00 (6.00, 9.00) | 0.006 |
| MEQ, median (IQR)                      | 54.00 (48.00, 62.50) | 56.00 (50.00, 64.00) | 0.436 |

experienced VM attacks in early hours of a day (00:00:00–12:00:00) had more severe headaches or vestibular symptoms; (2) severity of attack was associated with duration of illness and sleeping disruption. To our knowledge, this study was the first time to analyze the relationship between the time of onset and the severity of VM attack.

For most patients, VM is an episodic disorder with a combination of headache and vestibular symptoms; the duration of attacks ranges from seconds to days (4, 19). Relapses of dizziness or headache tend to be longer with VM and occur up to several times per year, compared to relapsing migraine having episodes once every few weeks (20, 21). However, the frequency of VM attacks was slightly lower in our cohort. Although no long-term migraine-suppressing drugs had been used, most participants reported only one attack during follow-up, which may be related to the subjective discomfort and self-avoidance of triggers. Thus, this issue may be further examined in VM patients in future studies.

VM may be more common in women; however, the specific proportion is quite different in different studies (5, 9, 12, 22). A recent retrospective study in Italy showed a higher probability of variability and onset with increasing age in VM patients (23). Meantime, elderly women were more often affected than elderly men (23). A systematic review of Germany reveals that disease severity has also been reported to vary over time (24). Although there were few studies on the natural history and related mechanisms in patients with VM, some reasonable hypotheses have been put forward on the fact that migraine and VM may share some common pathophysiology. This phenomenon may be related to the sharing of central and peripheral vestibular structures in older age (25). Aging affects the saccular function and its central processing in the vestibular nucleus and vestibulospinal tract (25). It is particularly true for the period from pre-school age to puberty and elderly patients (5, 12, 25). These findings are consistent with our results that VM patients with a longer history had more severe attacks. Considering that VM and migraine partly share some neural circuits, including thalamus and amygdala, hormone triggering may play an important role in age-related variability in the clinical presentation of VM (4, 12, 26). A recent study showed systemic hormone factors like hyperthyroidism could hasten age-related deterioration of saccule-related neural function (25). Among the participants, especially among the elderly, women were obviously dominant, which indirectly demonstrated this point (23).

Migraine shows circadian variation in the occurrence and clinical presentation (21). Previous studies had suggested that migraine headache characteristics, such as severe headache intensities were most frequent between 06:00 and 11:59 (21, 27). VM as a variant of migraine, also showed similar circadian rhythms in our study. About 73.6% patients experienced VM attacks in early hours of a day and the time of onset was associated with the severity of attack assessed by VAS. Meanwhile, we found poor sleep quality, as a clinical common inducement, was associated with severity of VM attack. Latest study had shown that VM patients had worse sleep quality than migraine patients and normal subjects (22). VM may cause structural sleep disorders by affecting sleep regulation centers (22). A recent study with a large sample size by Kim et al. also showed a correlation between vestibular-related diseases (including VM) and sleep disorders (28). In Furman’s VM pathophysiology model, the hypothalamus is included in the network of vestibular, visceral...
|                              | Time of onset | Male | Age | Age offirst onset | Duration ofillness | Alcohol consumption | Caffeine consumption | High-fat diet | History ofmotion sickness | Family history | Ictal aural symptoms | Visual symptoms | Length ofspell | VAS | GAD-7 | PHQ-9 | PSQI | MEQ |
|------------------------------|---------------|------|-----|-------------------|-------------------|--------------------|--------------------|--------------|--------------------------|----------------|------------------------|----------------|---------------|-----|--------|--------|------|-----|   |
| **Time of onset**            | 1             | 0.059 | 0.002 | 0.019 | -0.021 | 0.109 | -0.050 | 0.022 | -0.160 | 0.120 | 0.087 | 0.114 | -0.003 | -0.342 | -0.402 | -0.043 | -0.232 | 0.237 |
| **Male**                     | I             | 0.059 | 0.000 | 0.025 | -0.027 | 0.047 | 0.075 | -0.126 | -0.063 | -0.151 | 0.118 | -0.109 | 0.055 | 0.039 | 0.028 | -0.043 | 0.007 | 0.024 |
| **Age**                      | 0.002          | 0.000 | 1    | 0.760 | 0.547 | -0.170 | 0.071 | -0.189 | -0.150 | -0.054 | -0.071 | -0.013 | 0.089 | 0.142 | -0.052 | 0.128 | -0.080 | 0.042 |
| **Age offirst onset**        | 0.019          | 0.025 | 0.760 | 1     | -0.128 | -0.146 | 0.131 | -0.152 | -0.107 | -0.063 | 0.002 | 0.018 | 0.050 | 0.089 | -0.045 | 0.157 | -0.067 | 0.030 |
| **Duration ofillness**       | -0.021         | -0.027 | 0.547 | -0.128 | 1     | -0.075 | -0.061 | -0.094 | -0.094 | -0.004 | -0.114 | -0.045 | 0.072 | 0.105 | -0.023 | -0.007 | -0.035 | 0.026 |
| **Alcohol consumption**      | 0.109          | 0.047 | -0.170 | -0.146 | -0.075 | 1     | -0.002 | 0.510 | 0.025 | 0.164 | 0.079 | 0.076 | 0.146 | -0.024 | 0.072 | 0.033 | -0.093 | 0.085 |
| **Caffeine consumption**     | -0.050         | 0.075 | 0.071 | 0.131 | -0.061 | -0.002 | 1     | 0.232 | -0.054 | -0.090 | -0.082 | -0.083 | -0.008 | 0.007 | -0.018 | 0.032 | 0.030 | 0.040 |
| **High-fat diet**            | 0.022          | -0.128 | -0.189 | -0.152 | -0.094 | 0.510 | 0.232 | 1     | 0.037 | 0.066 | -0.039 | 0.088 | 0.020 | -0.028 | -0.030 | -0.023 | 0.012 | 0.121 |
| **History ofmotion sickness**| -0.160         | -0.063 | -0.150 | -0.107 | -0.094 | 0.025 | -0.054 | 0.037 | 1     | 0.151 | 0.031 | 0.005 | -0.031 | 0.047 | 0.074 | 0.122 | 0.157 | -0.011 |
| **Family history**           | 0.120          | -0.151 | -0.054 | -0.063 | -0.004 | 0.164 | -0.090 | 0.065 | 0.151 | 1     | 0.113 | 0.014 | 0.108 | 0.016 | -0.034 | -0.001 | 0.003 | 0.073 |
| **Ictal aural symptoms**     | 0.087          | 0.118 | -0.071 | 0.002 | -0.114 | 0.079 | -0.082 | -0.039 | 0.031 | 0.113 | 1     | 0.091 | -0.114 | 0.027 | 0.005 | -0.010 | -0.032 | 0.032 |
| **Visual symptoms**          | 0.114          | -0.109 | -0.013 | 0.018 | -0.045 | 0.076 | -0.083 | 0.098 | 0.005 | 0.014 | 0.091 | 1     | 0.003 | -0.116 | 0.048 | -0.037 | 0.022 | 0.088 |
| **Length ofspell**           | -0.003         | 0.055 | 0.089 | 0.050 | 0.072 | 0.146 | -0.008 | 0.020 | -0.031 | 0.108 | -0.114 | 0.003 | 1     | -0.033 | 0.021 | -0.034 | -0.100 | 0.068 |
| **VAS**                      | -0.342         | 0.039 | 0.142 | 0.089 | 0.105 | -0.024 | 0.007 | -0.028 | 0.047 | 0.016 | 0.027 | -0.116 | -0.033 | 1     | 0.175 | 0.085 | 0.233 | -0.132 |
| **GAD-7**                    | -0.402         | 0.028 | -0.052 | -0.045 | -0.023 | 0.072 | -0.018 | -0.030 | 0.074 | -0.034 | 0.005 | 0.048 | 0.021 | 0.175 | 1     | 0.218 | 0.129 | -0.012 |
| **PHQ-9**                    | -0.043         | -0.043 | 0.128 | 0.157 | -0.007 | 0.033 | 0.032 | -0.023 | 0.122 | -0.001 | -0.010 | -0.037 | -0.004 | 0.085 | 0.218 | 1     | 0.021 | 0.020 |
| **PSQI**                     | -0.232         | 0.007 | -0.080 | -0.067 | -0.035 | -0.093 | 0.030 | 0.012 | 0.157 | 0.003 | -0.032 | 0.022 | -0.100 | 0.233 | 0.129 | 0.021 | 1     | -0.113 |
| **MEQ**                      | 0.237          | 0.024 | 0.042 | 0.030 | 0.026 | 0.085 | 0.040 | 0.121 | -0.011 | 0.073 | 0.032 | 0.088 | 0.058 | -0.132 | -0.012 | 0.020 | -0.113 | 1     |

*p < 0.05. **p < 0.001.
sensory and nociceptive information (6). The circadian rhythm is controlled by a complex system of molecular regulation with a master precursor, located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus (26, 29). Severity of VM attack was influenced by early circadian attack onset and induction of sleep quality, suggested that VM patients may have a different setting of the endogenous pacemaker in the suprachiasmatic nucleus (6). The circadian clock in the SCN is a complex network of heterogeneous neuronal and glial cells (30, 31). The most obvious circadian-regulated output is sleep and wake timing (6, 30, 31). Interestingly, the possible central pathogenesis of VM involves multiple sleep related nerve nuclei like the raphe nucleus, locus coeruleus and parabrachial nucleus, and the hypothalamus also plays a key regulatory role in sleep control. The locus coeruleus, as a regulatory target of central and vestibular conduction pathways in VM during an episode, which receives signals from hypothalamus (6, 30). Neuroanatomical studies have revealed a strong interaction between the vestibular system and noxious brainstem areas such as locus coeruleus, medial and lateral vestibular nuclei, and caudal trigeminal nucleus, which provides a basis for relationship between VM and sleep disorders (30). The trigeminal nerve and vascular reflex are activated in the inner ear in patients with VM, and the vestibular nucleus and pain system signal transduction is increased, suggesting that sleep disorders and other stress states may be triggering factors of VM (22). However, it is difficult to determine the causal relationship between circadian rhythmicity, sleep homeostasis, and VM on the available evidence. We can only preliminarily infer that the attack and severity of VM may be closely related to circadian rhythm and sleep homeostasis in VM patients.

Some studies have estimated that about 50% patients with VM have concomitant psychiatric disorders, most frequently is anxiety (19, 32). Our subjects excluded dizziness caused by subjective anxiety, thus minimizing the risk of inclusion bias. At the same time, anxiety may lead to the amplification of subjective discomfort caused by VM. It is more difficult to evaluate subjective reports in patients with decreased cognitive ability. However, our data suggested that severity of VM attack was not independently related with psychological factors, including anxiety.

Our data should be interpreted with some caution due to limitations of the study. Since the participants in this study were recruited only from two clinical unit, there may have retrospective bias inherent. CPSQI was used to assess sleep quality. Although this method is not the gold standard, it is a reliable method in population-based studies. The validity of the scale was further supported by the results that subjective sleep quality, sleep latency, sleep duration, and habitual sleep efficiency sub-scores significantly correlated to corresponding measures obtained by or derived from other instruments (16). We enrolled patients with probable VM, who might develop definite VM over time as some studies have shown (33–35). Moreover, we did not assess headache and vestibular symptoms separately, considering the complex temporal patterns between them (36). The exact clinical relevance needs to be further studied.

### CONCLUSION

In summary, patients tended to experienced more severe VM attacks in early hours of a day, especially for those sufferers with poor sleep quality. Therefore, appropriate management of sleeping problems may reduce the severity of attack in VM patients.

### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article-supplementary materials, further inquiries can be directed to the corresponding author/s.
ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

WL and YY designed the study. WL, HD, HZ, YY, and WD evaluated the subjects and collected the data. LY and YY analyzed the data. WL and HD wrote the initial draft, with YY and WD participating in revising the manuscript.

REFERENCES

1. Stolte B, Holle D, Naegel S, Diener HC, Obermann M. Vestibular migraine. Cephalalgia. (2015) 35:262–70. doi: 10.1177/0333102415535113
2. Maldonado Fernandez M, Birdi JS, Irving GJ, Murdin L, Kivekas J, Strupp M. Pharmacological agents for the prevention of vestibular migraine. Cochrane Database Syst Rev. (2015) 2005:CD010600. doi: 10.1002/14651858.CD010600.pub2
3. Teggi R, Colombo B, Albera R, Asprella Libonati G, Balzanelli C, Batuecas Calero A, et al. Clinical features, familial history, and migraine precursors in patients with definite vestibular migraine: the VM-phenotypes projects. Headache. (2018) 58:354–44. doi: 10.1111/head.13240
4. Lapira A. Vestibular migraine treatment and prevention. HNO. (2019) 67:425–8. doi: 10.1007/s00106-019-0661-3
5. Huang TC, Wang SJ, Kheradmand A. Vestibular migraine: an update on current understanding and future directions. Cephalalgia. (2020) 40:107–21. doi: 10.1177/03331024198963917
6. Furman JM, Marcus DA, Balaban CD. Vestibular migraine: clinical aspects and pathophysiology. Lancet Neurol. (2013) 12:706–15. doi: 10.1016/S1474-4422(13)70107-8
7. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. (2013) 33:629–808. doi: 10.1177/0333102413485658
8. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Furman JM, et al. Vestibular migraine: diagnostic criteria. J Vestib Res. (2012) 22:167–72. doi: 10.3323/VSRES-2012-0453
9. Bisodori A, Von Brevern M, Lempert T, Newman-Toker DE. Classification of vestibular symptoms: towards an international classification of vestibular disorders. J Vestib Res. (2009) 19:13–18. doi: 10.3323/VSRES-2009-0343
10. Weyers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. (1990) 13:227–36. doi: 10.1002/nur.4770130405
11. Celik O, Tanyeri Toker G, Eskiizmir G, Incesulu A, Sahin Suyur N. The effectiveness of medical prophylactic treatment on vestibular migraine and its effect on the quality of life. J Int Adv Otol. (2020) 16:28–33. doi: 10.15152/ioa.2019.6522
12. Beh SC, Masrou S, Smith SV, Friedman DI. The spectrum of vestibular migraine: clinical features, triggers, and examination findings. Headache. (2019) 59:727–40. doi: 10.1111/head.13484
13. Zhang W, Li F, Zhang T. Relationship of nocturnal concentrations of melatonin, gamma-aminobutyric acid and total antioxidants in peripheral blood with insomnia after stroke: study protocol for a prospective non-randomized controlled trial. Neurol Regen Res. (2017) 12:1299–307. doi: 10.4103/1673-5437.213550
14. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. (2006) 166:1092–7. doi: 10.1001/archinte.166.10.1092
15. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.016090060.x
16. Tsai PS, Wang SY, Wang MY, Su CT, Yang TT, Huang CJ, et al. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. Qual Life Res. (2005) 14:1943–52. doi: 10.1007/s11136-005-4346-x
17. Ferrara LA, Pacioni D, Di Fonzo V, Russo BF, Speranza E, Carlino V, et al. Low-liquid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis. (2015) 23:370–5. doi: 10.1016/j.nmcd.2014.12.006
18. Rist PM, Buring JE, Kurti T. Dietary patterns according to headache and migraine status: a cross-sectional study. Cephalalgia. (2015) 35:767–75. doi: 10.1177/0333102415600614
19. O’Connell Ferster AP, Prissol AI, Isildak H. The clinical manifestations of vestibular migraine: a review. Auris Nasus Larynx. (2017) 44:249–52. doi: 10.1016/j.anl.2017.01.014
20. Formeister EJ, Rizk HG, Kohn MA, Sharon JD. The epidemiology of vestibular migraine: a population-based survey study. Otol Neurotol. (2018) 39:1037–44. doi: 10.1177/MAO.000000000001900
21. Park JW, Cho SJ, Park SG, Chu MK. Circadian variations in the clinical presentation of headaches among migraineurs: a study using a smartphone headache diary. Chronobiol Int. (2018) 35:546–54. doi: 10.1080/07420528.2017.1420760
22. Wu J, Liu C, Yu H, Li H, Jia Y, Zhang D, et al. Clinical characteristics of sleep disorders in patients with vestibular migraine. Sleep Breath. (2019) 24:1383–88. doi: 10.1007/s11325-019-01994-4
23. Neuhauser HK. The epidemiology of dizziness and vertigo. Handb Clin Neurol. (2016) 137:67–82. doi: 10.1016/B978-0-444-63437-5.00005-4
24. Ori M, Arra G, Caricato M, Freccia R, Frati F, Bonis T, et al. Age-related features in vestibular migraine onset: a multiparametric analysis. Cephalalgia. (2020) 40:1605–13. doi: 10.1177/0333102420951505
25. Jung I, Ahn SH, Lee J, Lee SU, Oh HJ, Kim HJ, et al. Age-related deterioration of saccule-related neural function is associated with decreased estimated glomerular filtration rate and increased free thyroxine. Clin Neurophysiol. (2019) 130:795–801. doi: 10.1016/j.clinph.2019.02.002
26. Gaul C, Messlinger K, Holle-Lee D, Neeb L. Pathophysiology of headaches. Dtsch Med Wochenschr. (2017) 142:402–8. doi: 10.1055/s-0042-111694
27. van Oosterhout W, van Someren GG, Schoonman GG, Louter MA, Lammers GJ, Ferrari MD, et al. Chronotypes and circadian timing in migraine. Cephalalgia. (2018) 38:617–25. doi: 10.1177/0333102417769893
28. Kim SK, Kim JH, Jeon SS, Hong SM. Relationship between sleep quality and dizziness. PLoS ONE. (2018) 13:e0192705. doi: 10.1371/journal.pone.0192705
29. Dibner C, Schubler U. Circadian timing of metabolism in animal models and humans. J Intern Med. (2015) 277:513–27. doi: 10.1111/joim.12347
30. Schwartz WJ, Klerman EB. Circadian neurobiology and the physiological regulation of sleep and wakefulness. Neurology. (2016) 87:475–86. doi: 10.1016/j.ncl.2015.09.001
31. Hastings MH, Maywood ES, Brancaccio M. Generation of circadian rhythms in the suprachiasmatic nucleus. Nat Rev Neurosci. (2018) 19:453–69. doi: 10.1038/s41583-018-0026-2
32. Balaban CD, Jacob RG, Furman JM. Neurologic bases for comorbidity of balance disorders, anxiety disorders and migraine: neurotherapeutic implications. Expert Rev Neurother. (2011) 11:379–94. doi: 10.1586/ern.11.19
33. Van Ombergen A, Van Rompaey V, Van de Heyning P, Wuyts F. Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness. Otol Neurotol. (2015) 36:133–8. doi: 10.1097/MAO.0000000000000596
34. Eggers SD, Staab JP, Neff BA, Goulson AM, Carlson ML, Shepard NT. Investigation of the coherence of definite and probable vestibular migraine as distinct clinical entities. *Otol Neurotol.* (2011) 32:1144–51. doi: 10.1097/MAO.0b013e31822a1c67

35. Cho SJ, Kim BK, Kim BS, Kim JM, Kim SK, Moon HS, et al. Vestibular migraine in multiscenter neurology clinics according to the appendix criteria in the third beta edition of the International Classification of Headache Disorders. *Cephalalgia.* (2016) 36:454–62. doi: 10.1177/0333102415597890

36. Yan M, Guo X, Liu W, Lu J, Wang J, Hu L, et al. Temporal patterns of vertigo and migraine in vestibular migraine. *Front Neurosci.* (2020) 14:341. doi: 10.3389/fnins.2020.00341

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Liu, Dong, Yang, Zhao, Dong and Yang.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.